Consistent with those findings, we have observed from the data in The Cancer Genome Atlas prostate cancer that patients with high expression of UGT2B15 have increased risk of biochemical recurrence (Supplementary Figure S6). Here, UGT2B15 is linked to prostate carcinoma.